Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Large users of zopiclone assessed as impaired

30.03.2009
A new study from the Norwegian Institute of Public Health shows a positive link between the amount of the hypnotic (sleeping medicine) zopiclone in the blood and the chance of being assessed as impaired in a clinical examination. The study also included drivers who only showed alcohol in their blood test.

This could be important background knowledge in the discussion about establishing legal limits in traffic for sedatives or sleep-inducing medicines as we have for alcohol, says Ingebjørg Gustavsen from the Division for Forensic Toxicology and Drug Research.

Common sleeping medicines

Hypnotics that contain zopiclone and zolpidem (e.g. Imovane® and Stilnoct®) are widely used throughout the world and it is reported that between 3 and 7 % of the adult population uses these drugs. Researchers at the Norwegian Institute of Public Health have now studied if there is a link between the concentration of zopiclone or zolpidem in the blood and being assessed as impaired during a clinical examination. The study was done on anonymised material by comparing blood samples and results from clinical tests for the period January 2000 to December 2007. The same study was performed on another group of drivers who only had alcohol in the blood.

Link between substance concentration and impairment

The proportion of drivers who were evaluated as impaired increased with zopiclone-concentration in the blood. A similar positive link was not found for zolpidem. For alcohol, as expected, there was a significant link between the proportion of impaired drivers and alcohol concentration in the blood.

We know that the clinical examination performed on suspicion of driving under the influence is a test that is most sensitive for alcohol impairment, and less sensitive for other substances. Other types of impairment are therefore not necessarily picked up with this study, which can explain why we have not found positive links for zolpidem. Another reason can be that there were few drivers in our sample, particularly in the groups with low concentrations, says Gustavsen.

The proportion of drivers who were evaluated as impaired was relatively similar for the group that had 130 μg/l zopiclone or more in the blood and the group that had a blood alcohol concentration higher than 0.1 %. A concentration of 130 μg/l zopiclone in the blood suggests intake of at least 2 large doses of zopiclone.

Abuse potential

Zopiclone and zolpidem are usually used in moderate amounts before bedtime, and will often be excreted from the body by the next morning. There are few users of these hypnotics that are stopped by police based on suspicion of driving under the influence. In the meantime we know that these substances also have abuse potential, as do other sedative or sleep-inducing medicines. Over 90 % of the drivers included in the study because of zopiclone- / zolpidem-use had higher concentrations of the substances in the blood than one would expect from normal therapeutic use of sleeping tablets before bedtime, concludes Gustavsen.

Reference:
Gustavsen, I., et al., Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid. Anal. Prev. (2009), doi:10.1016/j.aap.2009.01.011

Julie Johansen | EurekAlert!
Further information:
http://www.fhi.no

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>